
Nicholas Short MD
@nicholasshortmd
Associate Professor, Department of Leukemia, MD Anderson Cancer Center - Research interest: phase I/II clinical trials in AML and ALL, developing new MRD assays
ID: 826584913214316546
https://faculty.mdanderson.org/profiles/nicholas_short.html 01-02-2017 00:16:15
346 Tweet
1,1K Followers
172 Following

Our paper on aza + ven +gilteritinib for FLT3mut #AML now online at Journal of Clinical Oncology In frontline FLT3mut AML, CR 90% (vs. 30-50% with aza+ven) and 18mo OS 72% (vs. 2yr OS 20-40% with aza+ven) Could be delivered safely with appropriate dose modifications. ascopubs.org/doi/10.1200/JC…



A very nice paper in Blood Journal elucidating the mechanisms of resistance to inotuzumab in B-ALL that go beyond loss of CD22 ashpublications.org/blood/article/…


Many pts with Ph+ #ALL can be salvaged with INO, blina or CAR T-cells after ponatinib failure. Long-term remissions possible in some pts without alloSCT Nicholas Short MD MD Anderson Cancer Center #Leukemia pubmed.ncbi.nlm.nih.gov/38607091/ AmericanJournalofHematology #leusm

Listening to #NicholasShort from MD Anderson Cancer Center talking about #inotuzumab in relapsed refractory Acute lymphoblastic leukemia! Delhi



NGS MRD (clonoSEQ) is the most sensitive and specific MRD assay in Ph+ #ALL. Therapeutic decision-making should be based on NGS rather than PCR for BCR::ABL1 Nicholas Short MD of MD Anderson Cancer Center #Leukemia doi.org/10.1080/174740… #leusm

Happy to see our trial of DAC, venetoclax and ponatinib for advanced phase CML published in The Lancet Haematology. Response rate was 80%, allowing for bridge to alloSCT. Still a lot more work to be done in this rare disease. We have new TKI combo studies now open and enrolling.

MRD is highly prognostic in #AML and can inform SCT decisions or enrollment into MRD-directed clinical trials. MRD endpoints may also allow for accelerated drug approval in AML. New review by Nicholas Short MD and Richard Dillon in AmericanJournalofHematology doi.org/10.1002/ajh.27… #leusm


Save the Date! calliecoombs John P. Leonard, MD Rami komrokji @farrukhawan Nicholas Short MD Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Krina Patel @corinneShahmehdi @jmaakaron Curtis Lachowiez Register at louisville.edu/medicine/cme/e… UofL Brown Cancer Center UofL Health UofL Medicine UofL Med School University of Louisville


CONGRESS #ASH24 | PRESENTATION Roberta Santos Azevedo, MD Anderson Cancer Center discussed older age and TP53 mutations as predictors of myeloid neoplasm. Incidence of t-MN was highest in pts older than 60, and also higher with treatment intensity and TP53 mutation. t-MN risk was highest


CONGRESS #ASH24 | PRESENTATION Walid Macaron, MD MSc, MD Anderson Cancer Center and BCMHouston discussed achievement of MRD negativity and positive long-term outcomes in B-ALL. In pts with PH- B-ALL , 2-yr RFS was higher in pts who were MRD neg after cycle 1, vs those who were pos after cycle 1.


CONGRESS | #ASH24 | PRESENTATION Nicholas Short MD MD Anderson Cancer Center shares long-term findings from a study of patients with ND FLT3m AML treated with HMA+Ven+FLT3i triplet (N = 73). ▪️Efficacy overall was comparable to that seen with doublet therapy, and at median follow-up of 26


Very nice of AmericanJournalofHematology to add a wonderful visual abstract to accompany our review article on MRD in AML. Link here: onlinelibrary.wiley.com/doi/10.1002/aj… Richard Dillon


Recommendations from a panel of US experts published in Blood Advances highlight the optimal use of MRD as a prognostic and therapeutic tool in adult ALL More news: loom.ly/EvtL7yw #ALLsm #leusm #MedNews #MedEd


Expert recommendations on using MRD in #ALL now out in Blood Advances. ClonoSEQ (NGS MRD) is superior to other MRD methods and should guide decisions about CAR T-cells or SCT MD Anderson Cancer Center #Leukemia doi.org/10.1182/blooda… #leusm


